McKesson to acquire Precision Medicine Group for ~$2.5bn

On 25 August 2026, McKesson Corporation announced a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma-commercialisation services, for approximately $2.25 billion. McKesson's own release doesn't break the consideration down into cash versus other components, and the deal is subject to customary closing conditions including regulatory clearances, with no specific expected closing date given.

McKesson is a large, diversified US healthcare-services company that distributes pharmaceuticals and provides related services to biopharma companies, care providers, pharmacies and others. Precision Medicine Group, based in Bethesda, Maryland, helps biotech and pharma companies take drugs from early research through to market, offering biomarker intelligence (lab testing that identifies measures biological signals used to select or track patients in a drug trial), lab services, a global CRO (contract research organisation, which is a company hired to run clinical trials on a drugmaker's behalf), market-access consulting, and commercialisation support, with a particular concentration in oncology trial work. Precision Medicine Group has been majority-owned by Blackstone since Blackstone took a stake in the business in November 2020.

This is a private M&A transaction. A straightforward purchase agreement between McKesson and Precision Medicine Group's owners (principally Blackstone), not a public-company takeover, so there's no share premium to calculate and no shareholder vote of the kind you'd see in a public deal. Once closed, Precision Medicine Group will sit inside McKesson's existing Oncology & Multispecialty segment.

There is no information on how McKesson is funding the purchase (cash on hand, new debt, or a mix). CitiGroup advised McKesson on the financial side, while Centerview Partners advised Precision Medicine Group. Davis Polk & Wardwell acted as McKesson's legal counsel. The partners in charge of the deal have both worked on McKesson deals before, including its 2024-2025 divestiture and acquisition activity (when a company buys another business or asset, while the other is when it sells a business or asset it already owns) in similar segments. Simpson Thacher & Bartlett acted for Precision Medicine Group, and by extension Blackstone as the selling shareholder.

For McKesson, this is a bolt-on (when a company buys a smaller, complementary business to add to and strengthen its existing operation) to its oncology strategy. It buys capability, through clinical trial execution, biomarker science, and commercialisation expertise, rather than just volume in a moment when McKesson has been vocal about shifting its portfolio towards higher-growth, higher-margin specialty and oncology services. For Blackstone, it's an exit from a five year old healthcare-services investment, consistent with a broader pattern of large PE firms rotating out of life-sciences adjacent platforms as strategic buyers with deeper pockets step in.

What does this mean for you? If you or someone you know is ever a participant in a cancer clinical trial in the US or Europe, Precision Medicine Group is one of the unseen companies that helps run that trial behind scenes. A change of ownership here is a story about who controls part of the infrastructure that gets new cancer treatments tested and approved. The deal is very unlikely to change drug prices at the pharmacy counter tomorrow. McKesson's statement frames this as strengthening "clinical trial execution" and broadening its "clinical trial offerings", which is corporate-speak for wanting to do more of this work in-house instead of relying on smaller, independent buyers. This is worth watching, speculatively, for whether that consolidation eventually narrows the number of independent CROs that biotech start-ups can shop between. No layoffs or restructuring have been announced, so this is a possible long-run effect, and not a confirmed one. There's no disclosed antitrust flag on this deal so far, likely because the market for clinical research is fragmented enough that a $2.25bn deal doesn't obviously raise competition concerns. This is just an inference, however, and not a certainty.